Gilead Sciences, Inc. is set to present new data at the San Antonio Breast Cancer Symposium (SABCS) 2023, highlighting the benefits of Trodelvy® (sacituzumab govitecan-hziy) for certain patients with metastatic triple-negative breast cancer (mTNBC) and HR+/HER2- metastatic breast cancer (mBC) who have received prior treatments. The presentations will include results from a clinical outcomes analysis based on age from the Phase 3 TROPiCS-02 study, as well as a qualitative analysis on the clinical meaningfulness of mBC treatments from the perspectives of patients, caregivers, and clinicians.

The SABCS 2023 will feature eight abstracts associated with Trodelvy, offering insights into its significant survival benefits for patients with second-line metastatic TNBC and pre-treated HR+/HER2- metastatic breast cancer. Bill Grossman, MD, PhD, from Gilead Oncology, emphasized the importance of Trodelvy as the first approved Trop-2-directed ADC that has shown survival improvement in these breast cancer populations. Additionally, Gilead will share real-world data highlighting quality of life and other health measures that are vital for treatment decision-making.

Trodelvy has been recommended as a category 1 preferred treatment for second-line mTNBC and metastatic HR+/HER2- breast cancer by the NCCN. The data presented at the symposium will enhance the understanding of Trodelvy’s role in treating difficult breast cancer types and provide deeper context for its use in clinical practice.

Source link:

author avatar
Ferry Darma
Ferry Darma is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.